UCB rises after MS upgrade to 'overweight'

UCB SA

23/06/2025 08:43

** Shares in UCB UCB.BR rise around 4% after Morgan Stanley upgrades the biopharmaceutical company to "overweight" from "equal-weight"

** The analysts say the recent pullback in shares overlooks the company's strong fundamentals, noting that forecast organic profit overshadows market rivals

** Up to the previous session's close, shares were down 18% YTD

** "(The) 2025-28 estimated organic profit growth nearly double that of sector peers", MS says

** The analysts add that trends are pointing to "positive tailwinds" in 2025 for UCB and its prescription drug Bimzelx, saying that underappreciated pipeline value offers "uniquely compelling" entry point for investors

** If shares hold gains, they will see their best day since May 2

** Out of 20 analysts that cover UCB, 14 rate the stock "strong buy" or "buy, while ​six rate it "hold" - LSEG data

 (Reporting by Mateusz Rabiega)

 ((Mateusz.rabiega@thomsonreuters.com;))